This site is intended for healthcare professionals

BioMarin provides highlights of 4 Years of clinical data from ongoing phase 1/II study of valoctocogene roxaparvovec gene therapy for severe hemophilia A.

Read time: 1 mins
Last updated:1st Jun 2020
Published:2nd Jun 2020
Condition: Haemophilia A
Type: drug
Register for free exclusive healthcare eLearning resources

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest